Topic

Articles

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

Avantor and Cytovance Biologics Partner on Plasmid DNA Development

Feliza Mirasol is the science editor for 

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Shining a Spotlight on Nucleic Acid-Based Therapeutics

GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.

USPTO Issues Malaria Vaccine Patent to GeoVax

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.

GSK to Acquire Sierra Oncology for $1.9 Billion

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

Developing Excipients for High-Concentration Biologic Formulations

Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.

Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH

Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Lonza and Asher Biotherapeutics have entered a manufacturing agreement for a cis-targeted IL-2 fusion protein, AB359.

Lonza and Asher Biotherapeutics to Collaborate on Manufacturing AB359

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

Evonetix Receives Patent for Thermally-Controlled DNA Synthesis Technology

NIH has announced four new grant awards to fund new tuberculosis research advancement centers. 

BioBusiness